GENESIS Ventures is an investment vehicle located in Barcelona and built up in partnership with family offices. The new fund is sized in 610.000 € and will invest in recently created Start-ups or entrepreneurial projects with a clear aim to develop innovative products through the creation of a Start-up company in the biomedical and biotechnological field (therapeutics, diagnostics, medical devices and others). The investment platform is envisaged as a very early-stage tool to help the development of excellent scientific projects to reach key value milestones to attract a first round of investment from venture or corporate funds.
Corify Care SL develops a medical device that non-invasively can see the electrical activity of the heart without the need of catheters or complex MRI/CT mappings. It offers ACORYS, a non-invasive electrocardiographic imaging device that resolves the main shortcomings of existing solutions to identify the optimal treatment in each patient with atrial fibrillation. The company was incorporated in 2019 and is based in Madrid, Spain.
MOWOOT is a Non-pharmacological & Non-invasive solution for people suffering from chronic constipation. Its solution is a wearable medical device, which provides an automatic colon-specific massage similar to the manual abdominal massage administered by health professionals. MOWOOT utilizes advanced pneumatic technology to treat and prevent chronic slow transit constipation without colon cleansing supplements, enemas, and laxatives. The company emerged out of the MOEBIO dHEALTH program, which is inspired by Stanford Biodesign and Kaospilot Design and Business School from Denmark. MOWOOT was founded in 2014 and is based in Barcelona, Spain.
ADmit Therapeutics, S.L. is a biotechnology company based in Begues, Spain, dedicated to the development of diagnostic tests for the early detection of Alzheimer’s disease. Founded in 2017, the company utilizes epigenetic analysis of blood samples to identify a series of mitochondrial biomarkers that are not related to traditional indicators such as ß-amyloid or tau proteins. By analyzing a large number of methylcytosines in mitochondrial DNA through next-generation sequencing, ADmit Therapeutics provides a novel and accessible method for medical practitioners to detect early-stage Alzheimer’s disease. Their innovative approach primarily serves pharmaceutical companies, aiming to enhance diagnostic capabilities in the field of neurodegenerative diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.